申请人:SELVITA SA
公开号:US20150274726A1
公开(公告)日:2015-10-01
Disclosed are substituted tricyclic benzimidazoles compounds as defined herein in formula (I) or pharmaceutically acceptable salts thereof. The compounds of the invention selectively inhibit CDK8 and are therefore useful for treating diseases related to this kinase, especially colorectal and melanoma cancers and other solid and hemathological malignancies, autoimmune diseases and inflammatory diseases. Also disclosed are processes for preparing these compounds.
本发明涉及以下式(I)中所定义的取代三环苯并咪唑化合物或其药学上可接受的盐。该发明的化合物具有选择性地抑制CDK8,因此可用于治疗与该激酶相关的疾病,特别是结肠直肠癌和黑色素瘤等实体和血液恶性肿瘤、自身免疫疾病和炎症性疾病。本发明还涉及制备这些化合物的过程。